HANGZHOU, China, Nov. 24 /PRNewswire/ -- Tigermed Consulting Co., Ltd., a leading Contract Research Organization (CRO) in China, announced that it has established strategic partnerships with two leading CROs, OCT in Russia and LSK in Korea respectively to integrate resources for the expansion and establishment of a global clinical trial network. This new strategic alliance spurs Tigermed to provide more extensive and comprehensive outsourcing clinical service for Multinational Pharmaceutical Corporations and Local Research Institutions in the research and development of innovative drugs.
Tigermed currently is ranked one of the largest Contract Research Organizations (CRO) in China, with a leading position in the Chinese clinical trial industry. Tigermed, staffed with a team of 100 professionals serving more than 150 local and global clients, has 15 offices in China and one office in the USA and a liaison office in Europe. The company's therapeutic strengths lie in areas such as oncology, biological vaccines, hepatitis, digestive system, cardiovascular and infectious diseases, in which Tigermed accumulated significant experience. Financed by Qiming Ventures, an internationally renowned venture capital organization, Tigermed now enters into a period of rapid expansion.
OCT, headquartered in Saint Petersburg, is a Russian CRO dedicated to clinical studies in Russia, Ukraine and other Eastern European countries. This strategic alliance with OCT facilitates Tigermed's expansion into these countries, and provides registration and clinical research services for Chinese Pharmaceutical Enterprises that have plans to enter into Eastern European markets.
LSK, headquartered in Seoul, is a leading CRO in Korea providing all
stages of clinical research services in Korea, Japan, Taiwan and Malaysia. The
strategic partnership with LSK enables Tigermed to extend its service
capabilities into Asia Pacific. Tigermed
'/>"/>
| SOURCE Tigermed Consulting Co., Ltd. Copyright©2008 PR Newswire. All rights reserved |